Cannara Biotech's Upcoming Financial Release
Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) is gearing up to announce its financial results for the fiscal fourth quarter and entire fiscal year. This news comes as anticipation builds regarding Cannara's performance and strategy moving forward.
Financial Results Announcement
The Company will share its financial updates on Monday, November 24, 2025, at 7:00 a.m. ET. This is an important moment for investors and stakeholders as it reflects Cannara's growth and strategies in the competitive cannabis market.
Webcast for Earnings Discussion
Following the release, Cannara's CEO Zohar Krivorot and CFO Nicholas Sosiak will host a webcast at 11:00 a.m. ET. This session will include prepared remarks and an opportunity for a live question-and-answer segment, allowing stakeholders to engage directly with the Company's leadership.
Investor Engagement Opportunities
Investors who cannot attend the live webcast will have the opportunity to access an archived version on Cannara's website, ensuring everyone has the chance to stay updated with the Company's developments. Prior to the session, investors are encouraged to mark their calendars and submit any questions ahead of time via email, which will be prioritized during the live event.
Board Update and Remembrance
In addition to the financial news, Cannara unfortunately announces the passing of Jack M. Kay, a valued member of its Board of Directors. Mr. Kay brought an impressive wealth of experience to the Company, having joined the Board in 2019. His contributions and years spent in executive positions, particularly at Apotex Inc., leave behind a lasting impact on the cannabis industry.
Remembering Jack M. Kay
Mr. Kay dedicated over three decades to Apotex, rising through ranks to hold several senior positions. He was not just a leader in pharmaceuticals but also an executive leader across various health sectors. His passion for community service showed through his role as Chairman of the Humber River Regional Hospital and involvement in numerous healthcare organizations.
About Cannara Biotech
Cannara Biotech Inc. continues to establish itself as a key player in the cannabis industry. The Company operates two robust facilities in Québec, which span more than 1,650,000 sq. ft., giving it a unique competitive edge in terms of production scale. With the ability to cultivate up to 100,000 kg yearly, Cannara leverages the province's low electricity costs to offer premium cannabis products at disruptive prices.
Commitment to Quality and Affordability
In a market often marked by inflation and fluctuations, Cannara's strategy focuses on maintaining quality while offering affordable options for consumers. With an ongoing commitment to excellence, Cannara remains dedicated to expanding its customer base and enhancing public awareness of its product offerings.
Contact Information
For any inquiries, investors can reach out to:
Nicholas Sosiak, CPA, CA
Chief Financial Officer
nick@cannara.ca
Zohar Krivorot
President & Chief Executive Officer
zohar@cannara.ca
Frequently Asked Questions
What are the upcoming financial results for Cannara Biotech?
Cannara Biotech will announce its financial results for Q4 and fiscal year 2025 on November 24, 2025.
Who will present at the earnings webcast?
The earnings webcast will be presented by CEO Zohar Krivorot and CFO Nicholas Sosiak.
How can investors submit questions for the earnings call?
Investors are encouraged to submit questions via email before the webcast for prioritization.
What is Cannara's commitment to the cannabis market?
Cannara aims to produce premium-grade cannabis products while keeping prices competitive, focusing on quality and customer satisfaction.
Who can I contact for more information about Cannara Biotech?
Interested parties can reach out to Nicholas Sosiak or Zohar Krivorot at their respective email addresses provided above.
